TY - CHAP M1 - Book, Section TI - Design and Optimization of Dosage Regimens: Pharmacokinetic Data A1 - Ragueneau-Majlessi, Isabelle A1 - Yu, Jingjing A1 - Isoherranen, Nina A2 - Brunton, Laurence L. A2 - Knollmann, Björn C. PY - 2023 T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition AB - This appendix provides a summary of basic pharmacokinetic information pertaining to small-molecule drugs that are in common clinical use and are delivered to the systemic circulation by parenteral or nonparenteral administration. Because of space limitations, this list cannot be exhaustive. Drugs designed exclusively for topical administration and not significantly absorbed into the bloodstream (e.g., ophthalmic and some dermal applications) are not included. A few other selection criteria have influenced the makeup of the list, but, in general, the authors have tried to include one or more representative drugs in each of the therapeutic areas in this text, based on distinct mechanism(s) of action. In some instances, drugs may be excluded because pharmacokinetics are not relevant to their therapeutic dosing regimen design. An obvious case is when drug efficacy is not apparently correlated with drug concentration in a reversible fashion (e.g., some cytotoxic anticancer drugs). In some instances, sufficient pharmacokinetic data are not available. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1193237254 ER -